This study, called DESTINY-Ovarian01, is looking at a new way to treat advanced ovarian cancer that has a specific marker called HER2. It compares two treatments: Trastuzumab Deruxtecan (T-DXd) combined with Bevacizumab, versus Bevacizumab alone. The goal is to see if the combination treatment can prevent the cancer from growing or spreading for longer. You might be able to join if you are an adult woman with HER2-expressing ovarian cancer. The main way we'll know if the treatment is successful is by measuring how long you live without the cancer getting worse. The study is currently unclear about its recruitment status and plans to enroll 582 participants.

Study design

This is an interventional study that will first have a safety run-in phase before a randomized phase. It plans to enroll 582 participants.

What's involved

You will need to sign consent forms before any testing. Trastuzumab Deruxtecan and Bevacizumab will be given intravenously (into a vein) every 3 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your progress will be followed from the date of randomization until radiographic disease progression or death, for up to approximately 35 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.